Introduction
MicroRNAs (miRNAs) are evolutionarily conserved post-transcriptional regulators and most of them are conserved from the unicellular algae Chlamydomonas reinhardtii to mitochondria, give a clue that they are a vital regulatory element in organisms (Molnár et al., 2007) . miRNAs are short non-coding RNA, ~22 nucleotide in size and do not code for any protein. In most of the cell types, they act as a negative regulator of gene expression when they bind to their target genes through watsoncrick base pairing between the miRNA 'seed region' and sequences commonly located in the 3' UTR, CDS and 5' UTR of multiple target mRNAs. When they bind with their target genes lead to repression of that protein-coding message, either by transcript destabilization, translational repression, or both (Lee, 2001 ).
More than 2588 mature miRNA have been documented in human, which may target about 60% of human genes (mirBase). A single miRNAs can target numerous mRNAs whereas individual mRNAs can be targeted by multiple miRNAs, providing vast regulatory potential (Peter, 2010) .
A large body of evidence suggests that widespread disruption of miRNA expression is frequently associated with human cancer. Deregulation of miRNAs has been proposed to contribute to oncogenesis in cancer (Croce, 2009; Kasinski and Frank, 2011) .
Various mechanisms are involved in alteration of miRNA expression in cancer that includes genetic alterations and epigenetic changes which can influence the processing and maturation of miRNA. miRNAs gene are frequently located in genomic fragile sites as well as in cancer-associated genomic regions that are known to be amplified in cancers (Croce, 2009; Kasinski and Frank, 2011) . miR-218 role in various cancers has been investigated and identified as a tumor suppressor miR. It has been found that miR-218 are down regulated in numerous cancers such breast cancer, brain tumor, oral squamous cell carcinoma, nasopharyngeal carcinoma and bladder cancer (Uesugi et al., 2011; Alajez et al., 2011; Tatarano et al., 2011) . Even though miR 218 de-gulation have been observed in various cancers, the mechanisms by which miR-218 is silenced has not been well established yet. In this study, we have identified how miRNA 218 expressions is epigenetically regulated along with its host gene breast cancer.
Materials and methods

Cell Lines and 5-azacytidine treatment
Breast cancer cell line, HCC712, was routinely maintained in RPMI 1640 supplemented with 10% FCS at 37°C, 5% CO2. The demethylating agent 5-azacytidine was prepared in DMSO and filter sterilized. Cells (5x10 5 ) were plated in a 25cm 2 flask in RPMI 1640 supplemented with 10% FCS. 24h later, cells were treated with 12.5 5µM of 5-azacytidine. The medium was changed every 24 h after treatment.
RNA was prepared 72h after treatment using the RNeasy kit (Qiagen) according the manufacturer's guidelines.
Quantitative real-time RT-PCR.
The expression levels of miR-218 (Assay ID: 000521 [Applied Biosystems]) were analyzed by TaqMan quantitative real-time PCR as described in the product manual and normalized to the expression of RNU48. QPCR for SLIT2, SLC6A1 and BCL11A was performed as described before (Dunwell et al., 2009 ).
Transfection of miR-218
The following mature miRNA was used in the present study: mature miRNA, PremiR miRNA Precursor (has-miR-218;). miR-218 (P ⁄ N: AM17100 [Applied Biosystems) was incubated with OPTI-MEM and Lipofectamine RNAiMax reagent (Invitrogen) as described in product manual. Realtime PCR confirmed transfection efficiency of mi-218. MTT Assays was performed as described in product manual (Catalog Number: TA5355/ rndsystems).
Results and Discussion
Genomic Organization miR-218
miR-218 is an intergenic miR, they are expressed by two different miR precursors, hsa-mir-218-1 and hsa-mir-218-2. These precursors are encoded in separate genomic locations, 4p15.31 and 5q35.1 respectively. miR-218-1 is housed in intron of SLIT2
where as 218-2 is resided in intron of SLIT3 (Figure1 1) . Scramble promoter region has been identified one of the frequently hyper methylated region in lung, pancreatic and breast cancer. In this study we report that miR-218 expression is regulated along with its host gene SLIT2 and SLIT3 through hyper methylation. It has been reported SLIT2 locus is hypermethylated in 36-53% of primary breast tumor.
When we treated the breast cancer cells with demethylatiing agent, 5-azacytidine, it strongly induced the expression miR-218 along with its host genes, SLIT2.
Meanwhile, 5-azacytidine suppressed the expression of miR-218 target genes SLC6A1 and BCL11A. This observation clearly indicates that expression of miR-218 is controlled by promoter hyper methylation of its hos genes. In addition, ectopic expression of miR-218 in breast cancer cell lines sensitize to doxorubicin treatment. It would be interesting to study further how the ectopic expression miR-218 along with its host genes together affects the cancer progression.
In conclusion, aberrant promoter methylation and associated transcriptional silencing of miR-218 along with its host genes. It suggests that miR-218 along with its host genes, SLIT2 might be amenable to therapeutic intervention by reversal of epigenetic inactivation.
